Literature DB >> 25515808

Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants.

Xiao-Bo Zhang1, Li-Juan Liu, Li-Ling Qian, Gao-Li Jiang, Chuan-Kai Wang, Pin Jia, Peng Shi, Jin Xu, Li-Bo Wang.   

Abstract

BACKGROUND: To investigate the clinical characteristics and analyze risk factors for severe respiratory syncytial virus (RSV) infection in hospitalized infants with acute lower respiratory tract infections (ALRIs).
METHODS: A retrospective review of the medical records of infants with RSV-associated ALRIs between March 1st, 2011 and February 29th, 2012 was conducted. Subjects were followed up over the phone or by outpatient visit six and twelve months after discharge.
RESULTS: Among 913 RSV-associated ALRIs infants, 288 (31.5%) had severe infections, which accounted for 4.2% of hospitalized children. The hospital RSV mortality rate was 1.0%. The proportions of cases with tachypnea, apnea, cyanosis, and fine rales were significantly higher in the severe ALRIs group (all P<0.001). Multivariate logistic regression showed that low-birth-weight [1.698 (1.028-2.805)], age less than 3 months old [3.385 (2.174-5.271)], congenital heart disease [1.667 (1.149-2.418)], bronchopulmonary dysplasia [8.505 (1.731-41.780)], and airway abnormalities [2.246 (1.008-5.005)] were independent risk factors for severe ALRIs. The incidence of bronchitis, pneumonia and readmission in the severe group was significantly higher than that of the non-severe group during the one-year follow-up (all P<0.001).
CONCLUSIONS: Younger age, low birth weight and underlying disease are associated with severe RSVassociated ALRIs. Furthermore, severe RSV infections may be associated with a higher frequency of subsequent bronchitis, pneumonia and re-hospitalization in the following year.

Entities:  

Mesh:

Year:  2014        PMID: 25515808     DOI: 10.1007/s12519-014-0513-x

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  20 in total

1.  [Guidelines for management of childhood community acquired pneumonia (for trial implementation) (I)].

Authors: 
Journal:  Zhonghua Er Ke Za Zhi       Date:  2007-02

2.  Variation in severity of respiratory syncytial virus infections with subtype.

Authors:  K M McConnochie; C B Hall; E E Walsh; K J Roghmann
Journal:  J Pediatr       Date:  1990-07       Impact factor: 4.406

3.  Association of radiologically ascertained pneumonia before age 3 yr with asthmalike symptoms and pulmonary function during childhood: a prospective study.

Authors:  J A Castro-Rodríguez; C J Holberg; A L Wright; M Halonen; L M Taussig; W J Morgan; F D Martinez
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

4.  Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group.

Authors:  X Carbonell-Estrany; J Quero; G Bustos; A Cotero; E Doménech; J Figueras-Aloy; J M Fraga; L G García; A García-Alix; M G Del Río; X Krauel; J B Sastre; E Narbona; V Roqués; S S Hernández; M Zapatero
Journal:  Pediatr Infect Dis J       Date:  2000-07       Impact factor: 2.129

5.  Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis.

Authors:  Kam Lun Hon; Ting Fan Leung; Wing Yee Cheng; Natalie Man Wai Ko; Wing Ki Tang; Win Win Wong; Wan Hang Prisca Yeung; Paul K S Chan
Journal:  J Crit Care       Date:  2012-01-09       Impact factor: 3.425

6.  Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.

Authors:  Rosalyn J Singleton; Dana Bruden; Lisa R Bulkow
Journal:  Pediatr Infect Dis J       Date:  2007-11       Impact factor: 2.129

7.  Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.

Authors:  K Grimwood; C Cohet; F J Rich; S Cheng; C Wood; N Redshaw; C W Cunningham; N Pearce; J R Kirman
Journal:  Epidemiol Infect       Date:  2008-01-04       Impact factor: 2.451

8.  Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis.

Authors:  Bernhard Resch
Journal:  Open Microbiol J       Date:  2014-07-11

9.  Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis.

Authors:  Mehmet Yekta Oncel; Sema Arayici; Gulsum Kadioglu Simsek; Erhan Calisici; Omer Erdeve; Nurdan Uras; Serife Suna Oguz; Ugur Dilmen
Journal:  Iran J Pediatr       Date:  2013-12       Impact factor: 0.364

10.  Epidemiology and risk factors for severe respiratory syncytial virus infections requiring pediatric intensive care admission in Hong Kong children.

Authors:  T F Leung; D S Y Lam; T Y Miu; K L Hon; C S K Chau; S W Ku; R S Y Lee; P Y Chow; W K Chiu; D K K Ng
Journal:  Infection       Date:  2013-11-26       Impact factor: 3.553

View more
  11 in total

1.  Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.

Authors:  Bosco Paes; Doyoung Kim; Mahwesh Saleem; Sophie Wong; Ian Mitchell; Krista L Lanctot
Journal:  Eur J Pediatr       Date:  2019-01-04       Impact factor: 3.183

2.  Clinical characterisation and phylogeny of respiratory syncytial virus infection in hospitalised children at Red Cross War Memorial Children's Hospital, Cape Town.

Authors:  Regina Oladokun; Rudzani Muloiwa; Nei-Yuan Hsiao; Ziyaad Valley-Omar; James Nuttall; Brian Eley
Journal:  BMC Infect Dis       Date:  2016-05-31       Impact factor: 3.090

Review 3.  Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis.

Authors:  Renato T Stein; Louis J Bont; Heather Zar; Fernando P Polack; Caroline Park; Ami Claxton; Gerald Borok; Yekaterina Butylkova; Colleen Wegzyn
Journal:  Pediatr Pulmonol       Date:  2016-10-14

4.  Clinical and Epidemiologic Characteristics of Hospitalized Patients with Laboratory-Confirmed Respiratory Syncytial Virus Infection in Eastern China between 2009 and 2013: A Retrospective Study.

Authors:  Dawei Cui; Luzhao Feng; Yu Chen; Shengjie Lai; Zike Zhang; Fei Yu; Shufa Zheng; Zhongjie Li; Hongjie Yu
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

5.  Etiology of severe pneumonia in Ecuadorian children.

Authors:  Sivani Jonnalagadda; Oswaldo Rodríguez; Bertha Estrella; Lora L Sabin; Fernando Sempértegui; Davidson H Hamer
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

6.  Inter-individual variation in health and disease associated with pulmonary infectious agents.

Authors:  Kirsten C Verhein; Heather L Vellers; Steven R Kleeberger
Journal:  Mamm Genome       Date:  2018-02       Impact factor: 2.957

7.  Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors.

Authors:  Nijolė Drazdienė; Rasa Tamelienė; Daiga Kviluna; Pille Saik; Ervin Saik; Jolanta Zaikauskienė
Journal:  Acta Med Litu       Date:  2018

8.  Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).

Authors:  Zbyněk Straňák; Elie Saliba; Paraskevi Kosma; Klara Posfay-Barbe; Khalid Yunis; Teresa Farstad; Kristina Unnebrink; Jean van Wyk; Colleen Wegzyn; Gerard Notario; Stefanie Kalus; Fiona J Campbell
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

9.  Molecular epidemiology of human respiratory syncytial virus among children in Japan during three seasons and hospitalization risk of genotype ON1.

Authors:  Akinobu Hibino; Reiko Saito; Kiyosu Taniguchi; Hassan Zaraket; Yugo Shobugawa; Tamano Matsui; Hiroshi Suzuki
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

10.  Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.

Authors:  Manuel Sánchez-Luna; Constancio Medrano; Julián Lirio
Journal:  Influenza Other Respir Viruses       Date:  2016-12-30       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.